174900.KQ
AbClon Inc.
KOE · Healthcare · Biotechnology · KR
KRW 20,400.00
−8.52%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 5.3B | 4.7B | 2.3B | 3.1B | 3.4B |
| Cost of Revenue | 5.0B | 4.7B | 1.3B | 874.4M | 1.0B |
| Gross Profit | 268.3M | 24.0M | 1.1B | 2.2B | 2.4B |
| Operating Expenses | |||||
| R&D Expense | 13.9B | 13.6B | 13.4B | 10.7B | 8.7B |
| SG&A Expense | 1.8B | 1.4B | 912.0M | 828.9M | 707.4M |
| General & Admin Expense | 88.3M | 216.4M | 437.3M | 251.4M | 89.2M |
| Selling & Marketing Expense | 596.0M | 1.2B | 474.7M | 577.5M | 618.1M |
| Other Expenses | 6.8B | 2.9B | 2.4B | 2.2B | 29.8M |
| Total Operating Expenses | 18.2B | 17.9B | 16.7B | 13.7B | 11.1B |
| Cost and Expenses | 23.3B | 22.6B | 17.9B | 14.6B | 12.2B |
| Operating Income (EBIT) | (18.2B) | (17.9B) | (15.6B) | (11.5B) | (8.7B) |
| Non-Operating | |||||
| Interest Income | 890.6M | 457.7M | 360.3M | 860.2M | 258.8M |
| Interest Expense | 327.1M | 438.7M | 900.1M | 1.4B | 489.6M |
| Net Interest Income | 563.5M | 19.0M | (539.8M) | (490.2M) | (230.7M) |
| Other Non-Op Income/Expense | 890.2M | (24.3M) | (712.6M) | (1.2B) | (1.6B) |
| Non-Operating Income (excl Interest) | (113.3M) | — | (187.4M) | 36.7M | 1.1B |
| EBT (Pre-Tax Income) | (17.3B) | (17.9B) | (16.3B) | (12.8B) | (10.3B) |
| Income Tax Expense | (2.4M) | (2.4M) | — | 11.0M | (1.1B) |
| Bottom Line | |||||
| Net Income | (17.4B) | (17.9B) | (16.3B) | (12.8B) | (9.3B) |
| Earnings from Cont. Ops | (17.4B) | (17.9B) | (16.3B) | (12.8B) | (9.3B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (17.6B) | (17.9B) | (16.3B) | (12.9B) | (9.3B) |
| Per Share | |||||
| Basic EPS | (₩903) | (₩965) | (₩942) | (₩850) | (₩612) |
| Diluted EPS | (₩903) | (₩965) | (₩942) | (₩840) | (₩612) |
| Revenue Per Share | ₩266 | ₩246 | ₩135 | ₩203 | ₩225 |
| Shares | |||||
| Basic Shares Outstanding | 19.9M | 19.1M | 17.3M | 15.2M | 15.1M |
| Diluted Shares Outstanding | 19.9M | 19.1M | 17.3M | 15.4M | 15.1M |
| Profitability Metrics | |||||
| EBITDA | (23.1B) | (16.8B) | (13.8B) | (9.9B) | (8.3B) |
| D&A | 859.3M | 1.1B | 1.6B | 1.7B | 1.5B |
| EBIT | (24.0B) | (17.9B) | (15.4B) | (11.5B) | (9.9B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026